Dr. Kuykendall on the Potential for Momelotinib in Myelofibrosis
Andrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.
Andrew T. Kuykendall, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.
Momelotinib is a JAK inhibitor that is currently under investigation in this patient population, and that has been associated with improvements in cytopenias, such as anemia, in the phase 3 Simplify 1 (NCT01969838) and Simplify 2 (NCT02101268) trials, according to Kuykendall. Additionally, the agent is being examined in the randomized phase 3 MOMENTUM trial (NCT04173494), where it is being compared with danazol, Kuykendall explains.
The drug may have the potential to transform the treatment paradigm for patients who experience cytopenias and splenomegaly, as well as for those who need help managing anemia, spleen size, and other symptoms, Kuykendall adds. As such, the results of the trial are highly anticipated to determine whether momelotinib will be an option for these patients, Kuykendall concludes.
